Alveolar-capillary membrane permeability for early prediction of response of inhaled steroid on patients with chronic obstructive pulmonary disease

Journal of Clinical Pharmacy and Therapeutics

Volumn 31, Issue 4, 2006, Pages 363-368

  Chou, S H ^a   Chen, Y W ^a   Chuang, H Y ^a   Kao, E L ^a   Huang, M F ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Alveolar capillary permeability; Chronic obstructive pulmonary disease; Inhaled corticosteroid

Indexed keywords

BUDESONIDE; DUASMA; PENTETATE TECHNETIUM TC 99M; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; CAPILLARY PERMEABILITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG PENETRATION; DRUG RESPONSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG ALVEOLUS; MALE; PREDICTION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; BRONCHODILATOR AGENTS; CASE-CONTROL STUDIES; CELL MEMBRANE PERMEABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 33745955585     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2006.00751.x     Document Type: Article

References (30)

1. Murray CJ, Lopez AD (1997) Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet, 349, 1436-1442.
2. Laurell CB, Eriksson S (1963) The electrophoretic alpha-1 globulin pattern of serum in alpha-1 antitrypsin deficiency. Scandinavian Journal of Clinical and Laboratory Investigation, 15, 132-140.
3. Hubbard RC, Crystal RG (1991) Antiproteases. In: Crystal RB, West JB, Barnes PJ, Cherniack NS, Weibel ER, eds. The lung: scientific foundation. New York: Raven Press, 1775-1787.
4. MCElvaney NG, Crystal RG (1997) Inherited susceptibility of the lung to proteolytic injury. In: Crystal RG, West JB, Weibel ER, Barnes PJ, eds. The lung: scientific foundations, 2nd edn. Philadelphia, PA: Lippincott-Raven, 2537-2553.
5. Buist AS, Vollmer WM (1994) Smoking and other risk factors. In: JF Murray, JA Nadel, eds. Textbook of respiratory medicine. Philadelphia, PA: W.B. Saunders, 1259-1287.
6. Leuenberger P, Schwartz J, Ackermann-Liebrich U et al. (1994) Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study). Swiss Study on Air Pollution and Lung Diseases in Adults, SAPALDIA Team. American Journal of Respiratory and Critical Care Medicine, 150, 1222-1228.
7. Dayal HH, Khuder S, Sharrar R, Trieff N (1994) Passive smoking in obstructive respiratory disease in an industrialized urban population. Environmental Research, 65, 161-171.
8. Kauffmann F, Drouet D, Lellouch J, Brille D (1979) Twelve years spirometric changes among Paris area workers. International Journal of Epidemiology, 8, 201-212.
9. Niewoehner DE (1998) Anatomic and pathophysiological correlations in COPD. In: Baum GL, Crapo JD, Celli BR, Karlinsky JB, eds. Textbook of pulmonary disease. Philadelphia, PA: Lippincott-Raven, 823-842.
10. Mullen JB, Wright JL, Wiggs BR, Pare PD, Hogg JC (1985) Reassessment of inflammation of airways in chronic bronchitis. British Medical Journal (Clinical Research Edition), 291, 1235-1239.
11. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK (1997) Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. American Journal of Respiratory and Critical Care Medicine, 155, 852-857.
12. Saetta M, Di Stefano A, Maestrelli P et al. (1993) Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. The American Review of Respiratory Disease, 147, 301-306.
13. McLean KA (1958) Pathogenesis of pulmonary emphysema. American Journal of Medicine, 25, 62-74.
14. Wright JL, Lawson L, Pare PD et al. (1983) The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease: the effect of oxygen and exercise. The American Review of Respiratory Disease, 128, 702-707.
15. Peinado VI, Barbera JA, Abate P et al. (1999) Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 159, 1605-1611.
16. Yamamoto C, Yoneda T, Yoshikawa M et al. (1997) Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest, 112, 505-510.
17. Hill AT, Bayley D, Stockley RA (1999) The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. American Journal of Respiratory and Critical Care Medicine, 160, 893-898.
18. Keatings VM, Collins PD, Scott DM, Barnes PJ (1996) Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. American Journal of Respiratory and Critical Care Medicine, 153, 530-534.
19. Reis AL (1982) Response to bronchodilators. In: Clausen J, ed. Pulmonary function testing: guidelines and controversies. New York: Academic Press, 1-368.
20. American Thoracic Society (1991) Lung function testing: selection of reference values and interpretative strategies. The American Review of Respiratory Disease, 144, 1202-1218.
21. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee (2001) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. American Journal of Respiratory and Critical Care Medicine, 163, 1256-1276.
22. Todisco T, Dottorini M, Rossi F, Baldoncini A, Palumbo R (1989) Normal reference values for regional pulmonary peripheral airspace epithelial permeability. Influence of pneumonectomy and the smoking habit. Respiration, 55, 84-93.
23. Satub NC, Hyde RW, Crandall E (1990) NHLB workshop summary - workshop on techniques to evaluate lung alveolar microvascular injury. The American Review of Respiratory Disease, 141, 1071-1077.
24. Susskind H (1994) Technetium-99m-DTPA aerosol to measure alveolar-capillary membrane permeability. Journal of Nuclear Medicine, 35, 207-209.
25. Alsaeedi A, Sin DD, McAlister FA (2002) The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. American Journal of Medicine, 113, 59-65.
26. Lelwellyn-Jones CG, Harris TA, Stockley RA (1996) Effects of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. American Journal of Respiratory and Critical Care Medicine, 153, 616-621.
27. Confalonieri M, Mainardi E, Della Porta R et al. (1998) Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax, 53, 583-585.
28. Barnes PJ (1988) Airway pharmacology. In: Murray JF, Nadel JA, eds. Textbook of respiratory medicine. Philadelphia, PA: W.B. Saunders, 249-269.
29. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K (1999) Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 353, 1819-1823.
30. Senderovitz T, Vestbo J, Frandsen J et al. (1999) Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. Respiratory Medicine, 93, 715-718.